Genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation compared to pure urothelial carcinoma.

[1]  M. Maitituoheti,et al.  KMT2D deficiency confers a therapeutic vulnerability to glycolytic and IGFR inhibitors in melanoma , 2021, Molecular & cellular oncology.

[2]  X. Guan,et al.  995P A pan-cancer analysis of KMT2D as a potential biomarker for immune checkpoint therapy , 2021, Annals of Oncology.

[3]  T. Tsuzuki,et al.  Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis , 2021, BJU international.

[4]  E. Sokol,et al.  Clinically advanced pelvic squamous cell carcinomas (pSCC) in men and women: A comprehensive genomic profiling (CGP) study. , 2021 .

[5]  R. Montironi,et al.  Molecular Pathology of Urothelial Carcinoma. , 2021, Human pathology.

[6]  H. Kume,et al.  Squamous differentiation is a potential biomarker predicting tumor progression in patients treated with pembrolizumab for urothelial carcinoma. , 2021, Pathology, research and practice.

[7]  J. Southgate,et al.  Does a Novel Mutagenic Process Target KMT2D Mutation in the Most Common First Event on the Path to Bladder Cancer? , 2020, European urology.

[8]  Andrew Menzies,et al.  Extensive heterogeneity in somatic mutation and selection in the human bladder , 2020, Science.

[9]  S. Rozen.  Mutational selection in normal urothelium , 2020, Science.

[10]  W. Xie,et al.  Small molecule inhibitors of the prostate cancer target KMT2D. , 2020, Biochemical and biophysical research communications.

[11]  Ryan D. Chow,et al.  CRISPR-GEMM pooled mutagenic screening identifies KMT2D as a major modulator of immune checkpoint blockade. , 2020, Cancer discovery.

[12]  W. Sexton,et al.  Pathologic and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed with Cystectomy with or Without Neoadjuvant Chemotherapy. , 2020, The Journal of urology.

[13]  N. Agarwal,et al.  Histologic Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. , 2020, The Journal of urology.

[14]  A. Lopez‐Beltran,et al.  Variants and new entities of bladder cancer , 2018, Histopathology.

[15]  Mauro A. A. Castro,et al.  A Consensus Molecular Classification of Muscle-invasive Bladder Cancer , 2019, European urology.

[16]  B. Garcia,et al.  KMT2D regulates p63 target enhancers to coordinate epithelial homeostasis , 2018, Genes & development.

[17]  Steven J. M. Jones,et al.  Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer , 2017, Cell.

[18]  J. Kaouk,et al.  Patient Characteristics, Treatment Patterns and Prognostic Factors in Squamous Cell Bladder Cancer , 2017, Clinical genitourinary cancer.

[19]  K. Ge,et al.  Histone H3 lysine 4 methyltransferase KMT2D. , 2017, Gene.

[20]  G. Getz,et al.  Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise , 2015, Clinical Cancer Research.

[21]  W. Mackillop,et al.  Outcomes of squamous histology in bladder cancer: a population-based study. , 2015, Urologic oncology.

[22]  H. Kume,et al.  Squamous differentiation and prognosis in upper urinary tract urothelial carcinoma. , 2015, International journal of clinical and experimental pathology.

[23]  J. Gray,et al.  CUL4A induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression. , 2014, Cancer research.

[24]  P. Cagle,et al.  Tissue-preserving antibody cocktails to differentiate primary squamous cell carcinoma, adenocarcinoma, and small cell carcinoma of lung. , 2013, Archives of pathology & laboratory medicine.

[25]  C. Dinney,et al.  p63 Expression Defines a Lethal Subset of Muscle-Invasive Bladder Cancers , 2012, PloS one.

[26]  R. Babaian,et al.  Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  C. Dinney,et al.  The impact of variant histology on the outcome of bladder cancer treated with curative intent. , 2009, Urologic oncology.

[28]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .